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Clinical applications of oral protein therapy for the treatment of various chronic diseases are limited 
due to the harsh conditions encounter the proteins during their journey in the Gastrointestinal Tract. 
Although nanotechnology forms a platform for the development of oral protein formulations, obtaining 
physiochemically stable formulations able to deliver active proteins is still challenging because of 
harsh preparation conditions. This study proposes the use of poly (D, L-lactic-co-caprolactone)-
based polymeric nanocapsules at different monomers’ ratios for protein loading and oral delivery. 
All formulations had a spherical shape and nano-scale size, and lysozyme encapsulation efficiency 
reached 80% and significantly affected by monomers’ ratio. Trehalose and physical state of lysozyme 
had a significant effect on its biological activity (P < 0.05). Less than 10% of the protein was released in 
simulated gastric fluid, and 73% was the highest recorded accumulative release percentage in simulated 
intestinal fluid (SIF) over 24 h. The higher caprolactone content, the higher encapsulation efficiency (EE) 
and the lower SIF release recorded. Therefore, the formulation factors were optimised and the obtained 
system was PEGylated wisely to attain EE 80%, 81% SIF release within 24 h, and 98% lysozyme 
biological activity. The optimum formulation was prepared to deliver DNase, and similar attributes were 
obtained.
Drug delivery through the oral route of administration is the most common and acceptable systems due to their 
non-invasive and cost-effective properties. However, it is challenging to deliver the therapeutic proteins orally 
due to different hurdles; extreme stomach acidity, enzymatic degradation, physiological (permeability) barri-
ers, and physicochemical instabilities of proteins1,2. Although several novel protein delivery approaches have 
been developed, the parenteral dosage form is still the most common one2. Nanotechnology-based drug delivery 
systems have the potential to deliver therapeutic proteins orally3. The development of nanocarriers, e.g. lipos-
omes, noisomes, and polymeric nanoparticles was amongst the promising approaches attempted to overcome the 
obstacles facing oral protein delivery4–6. Moreover, several studies revealed that nanoparticles have an enormous 
impact on the oral bioavailability of biologic drugs including therapeutic proteins3,4,7–9. Polymeric nanocapsules 
(PNCs) comprise a core-shell structure in which proteins are confined and surrounded by a biodegradable pol-
ymer10,11. Nanocapsules system requires less amount of polymer contents to protect the vulnerable drugs12 and 
has the higher efficiency to encapsulate the drugs due to enhancing drugs solubility in the nanocapsules cavity13. 
Moreover, the revolution of polymer synthesis technology led to the development of aliphatic polyesters polymers 
which are biocompatible and biodegradable, therefore, less accumulation in tissues and less immune rejection14.
Polymeric nanocapsules are usually used in protein therapy to deliver the therapeutic proteins and improve 
their pharmacokinetics properties15, hence, reducing the frequency of administration and protecting them from 
GIT harsh conditions. Various material and process parameters may affect the attributes of nanocapsules, e.g. 
rate of drug release or the percentage of encapsulation efficiency. Therefore, selecting proper polymers is a crucial 
step in formulating the nanocapsules; due to their role in the determination of release rate, the biological activity 
of the encapsulated proteins, and the encapsulation efficiency16,17. Polylactide (PLA), polycaprolactone (PCL), 
polyethene glycol (PEG), polyglycolic acid (PGA), their copolymers are the most commonly used biodegradable 
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and biocompatible polymers for drug delivery purposes as they showed the promising results in term of biodistri-
bution16,18,19. Despite the high efficiency of PCL and its copolymers to confine the drugs inside them, their release 
profiles of macromolecules are poor, mainly when the copolymer comprises of PCL and another hydrophobic 
polyester polymer, e.g. PLA. The low percentage of protein release from PCL NCs is attributed to their innate 
hydrophobicity and permeability for small molecules but, not for macromolecules, because of the tiny pores on 
the polymers’ surface20. Encapsulating therapeutic proteins in polymeric nanocapsules is accompanied by several 
challenges. Denaturation of encapsulating protein is considered the most common drawback of protein loaded 
polymeric nanocapsules21. This denaturation may be caused by the harsh formulation process parameters and 
materials, e.g. sonication or the used organic materials22,23. Insertion of extremolyte sugars showed stabilising 
effects for the encapsulated proteins against the destabilising conditions; e.g. the biological activity of asparagi-
nase was improved by adding trehalose to the inner protein solution24. However, neither trehalose nor sucrose has 
any stabilising effect on lysozyme conformational and biological stability25,26. The failure of extremolytes to pro-
tect proteins may be attributed to several factors; their concentrations, the nature of polymers, or the ability of the 
polymers to confine the protein which may allow the leakage during and after the formulation process. Therefore, 
obtaining high encapsulated protein stability along with high encapsulation efficiency, high SIF release within 
the desired time, and protection against the gastric conditions is challenging. Thus, optimising these individual 
factors is crucial to attaining successful oral formulations.
To our knowledge, no studies so far have investigated the amount and physical state of trehalose required 
to prevent the denaturation of encapsulated proteins. Moreover, this is the first report utilises poly (D, L 
lactic-co-caprolactone) PLC to prepare PNCs intended for oral delivery. A copolymer comprised of lactide and 
ε-caprolactone was selected for their safety, biocompatibility biodegradability and enhanced pharmacokinetic 
properties as stated by27.
In this work, lysozyme/DNase-loaded polymeric nanocapsule formulations were prepared by modified double 
emulsion/evaporation method. The formulation plan of this study was according to a full design of experiment 
where the effect of different ratios of PLC monomers, and the quantity of added trehalose on solid and liquid 
lysozyme on the physicochemical properties of NCs, lysozyme release in SIG and SGF, and the biological activ-
ity of lysozyme was investigated. All factors were optimised, and PEGylated optimised formulation containing 
DNase as a therapeutic protein was prepared and characterised.
Results and Discussion
Formulation and physicochemical characterisation of polymeric nanocapsules. Lysozyme con-
taining PNCs were formulated using poly (D, L-Lactide-co-Caprolactone) (PLC) at two different ratios (86:14 or 
40:60) to encapsulate protein in liquid or solid state with different trehalose concentrations (1 mM and 10 mM). 
All factors were investigated together in a full factorial design of experiment rather than testing one factor at a 
time. All formulations were prepared either by S/O/W or W/O/W methods, Fig. 1.
Investigation of nanocapsules morphology by TEM revealed round core-shell structure with smooth external 
surfaces and particles of various size. Some of the agglomerates were also shown in the images with no noticeable 
Figure 1. Preparation of PNCs by double emulsification (w/o/w or s/o/w)/solvent evaporation method. 
Schematic representation of the formulation method of the protein-loaded PNCs. The PNCs were formulated 
by the emulsification of an internal aqueous phase (Protein and trehalose in water)/suspending of internal 
solid protein and trehalose into organic phase (ethyl acetate) containing polymers, and Span® 60. Then, further 
emulsification step has taken place between the internal (w/o or s/o) and an external aqueous phase (water, and 
PVA) using probe sonication. The solvent is removed forming PNCs aqueous dispersion. Finally, the formed 
suspension was lyophilised over 48 hours.
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difference in the shell thickness was noticed. The presence of the spots at the core of PNCs is supportive of the 
hypothesis that trehalose is encapsulated inside the polymeric shell. The spotty core was absent in the formula-
tions prepared with 1 mM trehalose, Fig. 2. Also, trehalose encapsulation was confirmed by utilising HPLC to 
detect peaks of trehalose. Data are provided in the supplementary information.
The hydrodynamic size obtained by dynamic light scattering was in the wide range of (325.3–865.3) nm, par-
ticle size distribution curves are provided in the supplementary information. None of the copolymers blocks ratio 
or the preparation method led to a statistically significant difference in PNC particle size (P > 0.05). However, 
high trehalose concentration increased PNC diameters (601–865 nm) significantly (P < 0.049), Table 1. This 
could be due to the accumulation of both protein and trehalose together in the core which may acquire a more 
substantial inner space. This assumption is supported by the observed spotty core in the presence of trehalose in 
the formulations, Fig. 2.
Unencapsulated protein was removed by centrifugation and, then, freeze-dried for 48 hours before finding the 
percentage of encapsulation efficiency. Protein encapsulation efficiency (EE%) for all formulations was quantified 
by size exclusion chromatography and described in Table 1. Values of EE% were obtained over a wide range (31.3–
69.3%) and significantly affected by the ratio of monomers (P < 0.0106). The higher ratio of ε-caprolactone the 
higher noticed EE%. Although trehalose and the physical state of proteins had no significant effect on EE%, uti-
lised DOE revealed a significant effect caused by the interaction between the physical state and copolymer ratio. 
Thus, a substantial increase in encapsulation efficiency was recorded when (40:60) PLC was used to encapsulate 
liquid lysozyme when compared to its ability to encapsulate lysozyme in the solid state. High EE% caused by the 
presence of a high ratio of ε-Caprolactone refers to the longer hydrocarbon chain of ε-Caprolactone, which helps 
to confine the protein and reduce the leakage to the outer aqueous medium during the emulsification process. 
Longer hydrocarbon chain accelerated the solidification of nanocapsule shell during organic phase evaporation. 
This rapid solidification could increase the polymer ability to confine the protein and reduce the amount of the 
leaked protein into the external aqueous medium.
In vitro release of lysozyme in Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF). 
The release of lysozyme from the polymeric Nanocapsules was investigated over 4 and 24 hours in SGF and SIF, 
respectively (Fig. 3), and the total percentage of lysozyme released is shown in Table 1. In SGF, release process was 
biphasic over 4 hours when an initial release phase (8%) was followed by an equilibrium state or slower release 
with an average overall release around 10.5% for all formulations (Fig. 3A). Whilst, a triphasic pattern represented 
the release of protein from the PNCs’ reservoir into SIF over 24 hours, which is concluded by; the initial burst 
phase of the proteins (8%) within the first 15 minutes. Then, a plateau for 8–10 hours reflecting equilibrium or a 
slow diffusion state in the second phase. Finally, sustained released was noticed over the rest of 24 hours (Fig. 3B). 
The secondary structure of released lysozyme in acidic and alkaline media was investigated by FTIR; the results 
revealed that lysozyme integrity was not affected after the release. FTIR data are included in SI.
Lysozyme release occurred via different mechanisms; the initial burst phase may have happened due to the 
adsorbed proteins at the PNCs surface. The second release phase or the plateau phase has resulted when adsorbed 
lysozyme on the inner polymer surface had diffused out28. Afterwards, the last sustained release phase usually 
results due to various mechanisms, e.g. particle structures weakening due to plasticising effect, or polymer degra-
dation and subsequent matrix erosion. Also, diffusion out of the polymer due to various causes, e.g. formation of 
some pores or water channels within polymer shells as medium penetrated the matrix particles may be the drug 
release mechanism.
In this study, the shape of nanocapsules was inspected just after the release by using TEM to figure out any 
shape changing in the nanocapsules structure. The spherical shape of PNCs was retained after protein release; 
however, the particle size was increased with some distortion of the particle surface, Fig. 3C. TEM images confirm 
Figure 2. Morphological examination polymeric PNCs by utilizing TEM. PNCs were prepared by double 
emulsification/solvent evaporation method. The images were taken by using negative staining technique 
(sodium silicotungstate solution). (A) TEM image for NC7 prepared by encapsulating solid lysozyme and 
10 mM trehalose in (86:14) PLC. (B) TEM image for NC3 prepared by encapsulating solid lysozyme with 1 mM 
trehalose in (86:14) PLC.
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Figure 3. In vitro release profile of lysozyme from PNCs in simulated gastrointestinal fluids (without enzyme) 
at 37 °C. Lysozyme release from PNCs was determined in simulation gastric fluids (SIF) and simulation 
intestinal fluid (SGF) for 4 and 24 hours, respectively. Both SIF and SGF were prepared according to British 
Pharmacopeia. However, no digestive enzymes were added. Protein release was determined by quantification of 
protein amount remaining in pellets by using SEC after pellets disruption and subtracting the remaining from 
the original value (100 μg) to find out release percentage. (A) The release profile of lysozyme in SGF over 4 h, 
where diphasic release pattern was noticed. (B) The release profile of lysozyme in SIF over 24 h, where triphasic 
release pattern of burst, plateau, and sustained release was noticed. (C) TEM images of PNCs after protein 












NC1 1 Liquid 14:86 467.1 ± 11.8 0.383 32.1% ± 2.8 13.05% ± 0.8 72.53% ± 4.0 43.56 1.28% ± 0.11%
NC2 1 Liquid 60:40 517.9 ± 46.7 0.384 68.4% ± 1.5 10.73% ± 4.0 32.38% ± 2.8 39.70 2.74% ± 0.06%
NC3 1 Solid 14:86 378.4 ± 32.5 0.335 39.3% ± 1.5 7.92% ± 1.9 64.36% ± 0.8 56.53 1.57% ± 0.06%
NC4 1 Solid 60:40 325.3 ± 14.5 0.291 62.3% ± 2.6 11.05% ± 1.9 30.95% ± 1.8 58.96 2.49% ± 010%
NC5 10 Liquid 14:86 831.9 ± 29.6 0.388 31.3% ± 2.7 10.84% ± 3.2 64.90% ± 2.4 79.24 1.25% ± 0.11%
NC6 10 Liquid 60:40 865.3 ± 22.6 0.382 69.2% ± 5.3 10.84% ± 2.9 38.52% ± 3.7 77.24 2.77% ± 0.21%
NC7 10 Solid 14:86 601.1 ± 9.7 0.346 41.5% ± 1.9 10.10% ± 3.4 68.53% ± 0.9 95.63 1.66% ± 0.08%
NC8 10 Solid 60:40 627.2 ± 39.6 0.366 64.1% ± 1.3 10.57% ± 3.5 35.68% ± 4.4 97.42 2.56% ± 0.05%
Table 1. Optimisation of the lysozyme-loaded NC formulations (model protein) and their physicochemical 
properties. aSize and PDI were measured by dynamic light scattering in deionised water. bResults are expressed 
as mean ± SD (n = 3). c% Encapsulation efficiency (%EE) of protein was determined by measuring absorbance 
at ƛ 21 nm in a size exclusion liquid chromatography. %EE was determined using the following equation: 
%EE = (amount of encapsulated protein/initially used protein) ∗ 100%. d% of total protein release in SGF after 
4 hours. e% of total protein release in SIF after 4 hours. fBiological activity was assessed by measuring the ability 
of encapsulated lysozyme to lysis the bacterial cell wall. g% Loading efficiency (%LE) of nanocapsules was 
calculated by using the following equation: %LE = (amount of encapsulated protein/amount of polymer used) * 
100%.
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that; no erosion occurred in the copolymers, and the release happened due to diffusion of the protein outside 
through the polymeric shells. When the PNCs were immersed in the aqueous medium (SIF), as direct contact 
between the polymeric outer shell and the aqueous medium plasticizes the polymer chains29,30, This allows further 
fluid influx into the inner core of the PNCs and eventually dissolved the protein and helped the PNCs to swell and 
generate some pores and increased the permeability due to its weakened and plasticised mechanical properties. 
Consequently, lysozyme started to efflux outside in a sustained manner with time.
The explanation was consistent with the study conducted by Blasi et al.29. Blasi et al.29 stated that; Tg of PLGA 
had been dropped by incubating in water at two different temperatures, i.e., 23 °C and 30 °C. Moreover, the same 
study showed that the decline in Tg was 15 °C after 1 hour of incubation irrespective of temperatures used. This 
depletion in Tg value has resulted in converting the polymer structure from the glassy state into a rubbery state, 
thus, increased the polymer fluidity, which consequently, may increase the drug release from polymeric drug 
delivery systems.
Statistical analysis revealed that total lysozyme released in SIF was significantly affected by the monomers’ 
ratio, where (86:14) PLC attained higher drug release over 24 hours.
D, L-lactide is the racemic form of Lactide moiety due to the presence of chiral methyl group in the Lactide. 
The molecule backing of racemic Lactide forms changed the mechanical properties from being crystalline or 
semi-crystalline to utterly amorphous form for the copolymer, which subsequently, decreases the polymer con-
sistency. This changing in internal structure decreases Tg, thus plasticizes the polymer and increases the per-
meability. The Poly (L-Lactide) form has 35:65 of crystalline: amorphous, while poly (D, L-Lactide) is entirely 
amorphous has a Tg value of 57 °C in comparison to pure poly(L-Lactide) (65 °C); which reflects different 
mechanical properties. Furthermore, forming copolymer can create new molecules with different mechanical 
properties, which may be able to reduce the rigidity of the polymers as described by31.
PLC 86%:14% has low Tg (16 °C)32. This depletion in Tg means that the copolymer gets plasticized and become 
rubbery at temperatures higher than 16 °C (body or release experiment temperature is 37 °C). However, 40:60 PLC 
has a melting temperature (Tm) of 31 °C32. Hence, mentioning melting temperature rather than glass transition 
temperature reflects that the polymer mainly consists of dominantly crystalline or semi-crystalline structure33. 
This means the polymer has more rigid and stable bond backing, thus confining lysozyme inside the polymeric 
system for a longer time due to slow release. The slow drug release of (40:60) PLC is caused by its slower softening 
rate when exposed to the dissolution condition at 37 °C when compared to (86:14) PLC.
The biological activity of encapsulated lysozyme. Encapsulated lysozyme retained 39.69–97.42% of 
their original activities, Table 1. Biological activity was increased significantly with increasing the amount of 
trehalose (p-value < 0.011) and encapsulating lysozyme in the solid state (p-value < 0.003), Fig. 4. Stability of 
Figure 4. 4D Response contour plot illustrating the effect of the investigated factors on the biological activity 
of lysozyme. The biological activity of lysozyme was measured by applying a predefined enzymatic assay which 
determines the ability of lysozyme to lysis the bacterial cell wall by breaking the b-1, the 4-glycosidic linkage 
between N-acetylglucosamine (NAG) and N-acetyl muramic acid (NAM) in Micrococcus lysodeikticus. UV-
visible spectroscopy was utilised to record the decrease in A450 over 5 minutes. The response plot illustrates the 
difference in biological activity between solid and liquid encapsulated lysozyme. Also, it shows how increasing 
the amount of used trehalose protected lysozyme significantly. Blue colour represented the least protected 
lysozyme (least biological activity), while, the red scale is for lysozyme retained high biological activity after 
encapsulation.
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lysozyme in solid state refers to the low rate of hydrolysis due to the absence of water34. Presence of water around 
lysozyme can cleave amide bonds and thus, denature the protein during the process of preparation35. The rate 
of chemical reaction of protein in the solid state is minimum due to the internal zero energy which protects the 
physical and chemical integrity of proteins36. Trehalose stabilises the proteins in solutions by preferential hydra-
tion mechanism and reducing the protein mobility which keeps the protein in the folded state37,38. Moreover, 
trehalose stabilises proteins by working as a water substitute during the lyophilization process by maintaining 
proteins’ hydrogen bonds, which eventually reduces the unfolding and protein deactivation39.
Trehalose stabilises solid proteins by so-called “Glass Dynamic Hypothesis”. The glass dynamic hypothesis 
states that trehalose forms rigid and inert solid filler around the proteins, which separates the protein molecules 
and inhibits any chance of protein motion and collision with other protein molecules. This eventually restricts the 
proteins unfolding and denaturation40.
Optimisation of formulation factors to prepare lysozyme/DNase-PNCs with optimum charac-
teristics. Altogether no formulation appeared to have optimum properties. Therefore, an optimising equation 
describing the best-fitted model was applied to optimise the factors to find the best-compromised responses. The 
optimised formulation is predicted to be prepared from 40:60 poly(D, L-Lactide-co-Caprolactone) to encapsulate 
solid lysozyme with 9 mM trehalose to obtain the following predicted responses; 70% EE% and 95% biological 
activity. However, release profile was predicted to stay low (36.5%) over 24 hrs even after optimisation; this is 
expected as high content PCL-NCs showed slow release kinetics. Several approaches could increase the release; 
however, not all of them are suitable for the other physicochemical properties. PEGylation is one of the most 
commonly used approaches in the preparation of polymeric nanocapsules due to its biocompatible nature and 
its ability to enhance drug release41,42.However, PEGylating time is critical as blending the used polymers with a 
hydrophilic polymer, e.g. PEG from primary stages may significantly reduce the encapsulation efficiency due to 
the leakage of protein into the outer aqueous phase during the process of the formulation43. Therefore, PEG 8000 
was selected due to its relatively high molecular weight and was added after the preparation and solidification of 
PNCs and just before the lyophilisation. The quantity of added PEG was optimised by adding different amounts 
to the formulation, Fig. 4. Four different formulations were prepared, and PEG was added in different quantities; 
10%, 15%, 25%, and 50%. The highest drug release in SIF was 92% and observed for PEG-PNC25% containing 
PEG, while 60.02% of lysozyme was released from the same formulation in SGF. Nevertheless, the release of SIF 
from PEG-PNC15% was 81.06%, but it suits the oral delivery more, as the release in SGF was 21.06%. Lysozyme 
release from the PEGylated and control (non-PEGylated) formulations was in the diphasic pattern except the 
release from PEG-PNC25% in SIF where triphasic was observed, Fig. 5.
Enhancing the systems’ release was caused by PNCs interaction with PEG which softened the polymer by 
increasing the water content it. Caprolactone is permeable to small molecules but, not macromolecules like pro-
tein because of the tiny pores on its surface20. PEG8000 may have increased the already existing pores by improv-
ing the permeability. However, increasing the quantity of PEG8000 to 50% w/w decreased the release percentage, 
and even less than the control formulations. After finding out the PEGylated PNCs morphology by TEM, a shield 
of PEG was formed around the particles which may hinder the release significantly, Fig. 4C.
Two PNCs optimised PEGylated formulations (15% PEG8000) were prepared and characterised for encapsu-
lation efficiency, drug release and biological activity. The obtained results were close to the predicted ones, where 
%EE 74.6%, 97% biological activity, and 82.15% SIF release were obtained.
Lysozyme was used as a model protein throughout the study. After optimising the factors and PEGylating the 
optimum formulation, PEG-PNCs15% was prepared to deliver deoxyribonuclease I (DNase I) and then charac-
terised. DNase is a therapeutic protein being used for the treatment of cystic fibrosis. The biological activity of 
encapsulated DNase I exceeded 95%, which reflects the ability of DNase to withstand during the process proce-
dures. Interestingly, the %EE, release profile in SIF, and release profile in SGF are comparable to those obtained 
from encapsulating lysozyme into PNCs at the same optimum conditions. The developed PNCs may present an 
excellent model for developing future polymeric nanocapsules containing other macromolecules, e.g. therapeutic 
proteins, monoclonal antibodies, and genes.
Conclusion
This is the first report on the investigation of trehalose quantity role in protecting proteins during the polymeric 
nanoencapsulation processes. Moreover, poly (D, L lactide-co-caprolactone) was utilised to prepare the PNCs 
for oral delivery, which also has never been studied before for oral delivery. Design of experiment was built to 
examine the effect of material attributes and optimise them to obtain PNCs with the desired %EE, release kinetics, 
particle size, and biological activity of proteins. The optimised formulation was capable of (i) retaining the high 
biological activity of encapsulated proteins, (ii) releasing high percentage of active proteins in SIF, (iii) obtaining 
a high percentage of encapsulation efficiency, and (iv) protecting the protein from degradation in gastric fluids. 
Herein, this data suggests that the biological activity of the protein was increased from 39% to 97% when the 
amount of trehalose used was increased from 1 mM to 10 mM. Also, high PCL content-copolymer could confine 
high percentage of protein. However, the extended release was observed. Therefore, high PCL-content PNCs was 
used to prepare the optimised formulation with using PEG as a release enhancer. PEGylated PLC-NCs confined 
more than 80% of the used protein and released 80% of the encapsulated protein in SIF. PEGylated PLC-NCs 
could be a promising nanocarrier system for oral delivery of therapeutic proteins. Lysozyme was used as a model 
protein throughout the study, in addition, PNCs containing DNase, as a therapeutic protein, were prepared at the 
optimised conditions.
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Experimental Sections
Materials. Lysozyme (Mucopeptide N-acetylmuramyl hydrolase, Muramidase, lyophilized powder, ≥40,000 
units/mg protein) obtained from chicken egg white, was provided by Sigma-Aldrich. Deoxy Ribonuclease I 
(DNase I lyophilized powder, ≥400 Kunitz units/mg protein) obtained from bovine pancreas, was provided by 
Sigma-Aldrich. Ethyl acetate, polyvinyl alcohol PVA, Span60®, DNA, Micrococcus lysodeikticus, pepsin, Poly 
(D, L-Lactide-co-Caprolactone) (40:60), Poly (D, L-Lactide-co-Caprolactone) (86:14), polyethylene glycol 8000 
(PEG 8000), and hydrochloric acid were purchased from Sigma–Aldrich Co. (Poole, Dorset, UK). Trehalose 
dihydrate was purchased from VWR Co., (Radnor, PA, USA). Electrochemical analysis grade acetonitrile was 
purchased from Fischer Scientific, (Loughborough, UK). Nano pure water (>Ω 18, Milli-Q) was obtained from a 
Diamond Lab Water System (Triple Red Laboratory Technology, Bucks, UK).
Design of Experiment. The design of experiment was selected to connect the overall quantitative data in 
the experiment in a lucid way. Therefore, the full experimental design was generated combining three factors 
each one has two levels to form eight different possibilities (23). The effect of the factors on the desired criteria 
(responses) was assessed by the preparation of formulations in triplicate and then characterise them in the light 
Figure 5. In vitro release profile of lysozyme from PEG-PNCs in simulated gastrointestinal fluids (without 
enzyme) at 37 °C. Lysozyme release from PEG-PNCs was determined in simulation gastric fluids (SIF) and 
simulation intestinal fluid (SGF) for 4 and 24 hours, respectively. Both SIF and SGF were prepared according 
to British Pharmacopeia. However, no digestive enzymes were added. Protein release was determined by 
quantification of protein amount remaining in pellets by using SEC after pellets disruption and subtracting the 
remaining from the original value (100 μg) to find out release percentage. PEGylation was by adding a different 
amount of PEG 8000 to the prepared formulations but before freeze drying. Percentage of PEG means the 
percentage of the weight of added PEG relatively to the weight of the initially used polymer. (A) The release 
profile of lysozyme in SGF over 4 h, where 25% PEG was adding has increased the release in SGF to around 60%. 
(B) The release profile of lysozyme in SIF over 24 h, when using of 15% and 25% of PEG resulted in very high 
drug release. (C) TEM images of 25% PEG-PNCs after protein release in SIF. The image demonstrates the large 
pores formed at the surface and facilitated the release of lysozyme. (D) TEM images of 50% PEG-PNCs after 
protein release in SIF. The image illustrates the formed shell around PNCs which is expected to have hindered 
lysozyme release.
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of the suggested qualities to screen the significance of each factor thus optimise them by utilising multilinear 
regression (MLR), Equation 1.
= β + β × + β × + β × × + … + εy 0 1 1 2 2 12 1 2 (1)
MODDE 10.1 software (Umetrics AB, Umea, Sweden) was utilised for statistical analysis.
PNCs preparation. Polymeric nanocapsule formulations were prepared by the double emulsion solvent 
evaporation method via preparing water in oil in water (W/O/W) emulsion as described by44. However, some 
formulations were developed by solid in oil in water S/O/W. Briefly, the w1 phase consisting of protein and treha-
lose dissolved in ultra-pure water (>Ω18) was dispersed into the ethyl acetate containing 1.67% w/v copolymer 
and 6% Span60 by probe sonication. Then, W/O emulsion was added to 50 ml of 3% PVA/water to prepare the 
secondary emulsion by probe sonication. Afterwards, the double emulsion was stirred overnight at the room 
temperature to evaporate the organic solvent and solidify the nanocapsules. The residues of organic solvent and 
free proteins were removed by centrifuging and washing the nanocapsules for times for 30 minutes at 15000 rpm 
and 4 °C before the lyophilization for 48 hours.
For the S/O/W preparations, the protein and trehalose were directly suspended in the organic phase and son-
icated to prepare the finely dispersed S/O suspension. Then, all the remaining steps same as W/O/W preparation 
method.
Encapsulation efficiency of proteins. Encapsulation efficiencies of the different formulations were meas-
ured by applying the previously developed method45. The polymeric shells were broken by suspending and stir-
ring the nanocapsules in ethyl acetate under fume cupboard for 2 hours. Then, it was centrifuged 2 times for 
10 minutes at 10000 rpm; the pellets were collected and left under the fume cupboard for half an hour to dry and 
then suspended in water and stirred for 2 hours until all the protein is dissolved. The suspension was centrifuged 
at 10000 rpm for 10 min, and then the supernatant was analysed, by using SEC, to determine the protein concen-
tration in the sample.
The particle size of protein polymeric nanocapsules measurement. Zeta PALS® dynamic light 
scattering was utilised to determine the nanocapsules containing proteins particle size. Samples were prepared 
by suspending 10 mg of the freeze-dried nanocapsules in 5 ml water. Afterwards, the resulting suspensions were 
mixed in the vortex for 1 minute and then were left in water bath sonicator for 5 minutes. Nanocapsule diameters 
were measured in triplicate at 25 °C.
Microscopic imaging of polymeric nanocapsules using Negative Staining Transmission Electron 
Microscopy (TEM). The morphology of PNCs was investigated by TEM. The technique was applied by using 
negative staining technique 1% (w/v) of sodium silicotungstate solution. A drop of PNCs suspension was applied 
on a 400 mesh Formvar copper grid on paraffin, and the sample was adhered on the Formvar at room temper-
ature for 15 minutes, then, a drop of 1% (w/v) of sodium silicotungstate solution was applied for 5 minutes. The 
obtained specimen was later observed under the TEM.
In vitro protein release in Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF) 
without enzymes. Protein release from the nanocapsules was determined in simulation gastric fluids (SGF) 
and simulated intestinal fluid (SIF) for 4 and 24 hours, respectively. Both SIF and SGF were prepared as per British 
Pharmacopeia 2014. However, no digestive enzymes were added.
Powder nanocapsules containing 1.5 mg entrapped protein, calculated based on relevant encapsulation effi-
ciency, were suspended in 30 ml SIF (pH 6.8), and in SGF (pH 1.2), then this volume was divided into 10 screw 
cap Eppendorfs, each contains 2 ml (100 μg protein). The vials were incubated in a shaker water bath under shak-
ing rate of 50 cycles/minute at 37 °C, and one vial was collected at each time point. All release tests were per-
formed in triplicate.
Eppendorf vials were taken, and the samples centrifuged 2 times at 10000 rpm for 10 minutes, the pellets 
were collected, and the shells were broken down. Then the remaining unreleased proteins were collected. Protein 
release was determined by quantification of protein amount remaining in pellets by using SEC after pellets disrup-
tion and subtracting the remaining from the original value (100 μg) to find out release percentage.
Measurement of biological activity of the encapsulated protein. The effect of the used reagents 
including polymers and encapsulation process on protein biological activities was examined in this study. PNCs 
shell was disrupted by adding ethyl acetate, and the biological activity of the encapsulated lysozyme was deter-
mined by its ability to lysis the bacterial cell wall. The calculation was performed by recording ΔA450 for the 
bacterial-lysozyme suspension over 5 minutes, as described previously by46. The biological activity of DNase I in 
this study was detected by applying the enzymatic assay procedures established by Kunitz 195047. The rate of the 
cleaving of phosphodiester linkage of DNA is considered as a function of DNAse I activity48.
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